Invivyd grants 157,500 options: what it means for Invivyd stock

Published on 10/14/2026 at 01:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Six new hires received options priced at USD 0.82 on October 1, 2026. Invivyd stock had a USD 190.3 million market value on October 13, 2026.

Option grant and clinical milestones

Invivyd disclosed 157,500 employee options on October 5, 2026.
The LIBERTY study enrolled 210 adults and reported 56.50 percent versus 91.40 percent for the vaccine arm.
Invivyd stock had a USD 190.3 million market value on October 13, 2026.
DECLARATION safety and immunogenicity data are expected in October 2026.

IVVD, US00534A1025, Illustration mit AI erstellt.

Invivyd, Inc. (ISIN US00534A1025) granted 157,500 stock options to six newly hired employees on October 1, 2026, a move reported on October 5 by GlobeNewswire. The options carried an exercise price of USD 0.82, rounded from USD 0.8165, and Invivyd stock had a USD 190.3 million market value on October 13, 2026.

Three milestones shape the setup

On August 13, 2026, Invivyd reported second-quarter revenue of USD 14.3 million, up 21.00 percent year over year, according to a Quartr summary of the company update. On September 29, 2026, Invivyd reported LIBERTY Phase 3 data from 210 healthy adults through its investor release. The October 5, 2026 option grant is the latest dated corporate event identified in the company release archive.

What the grant means for valuation

The more important valuation driver remains clinical execution. In LIBERTY, treatment-emergent adverse events, injection-site reactions or hypersensitivity affected 56.50 percent of VYD2311 recipients over six days, compared with 91.40 percent in the mRNA vaccine arm, according to Invivyd. The corresponding systemic adverse-event rates were 44.10 percent and 68.10 percent, giving the trial a clear numerical safety contrast while the company advances its regulatory plan.

DECLARATION data arrive in October

Invivyd said on September 29, 2026 that topline safety and immunogenicity data from the DECLARATION Phase 3 study were expected in October 2026, with the results intended to support a potential Biologics License Application through the FDA Accelerated Approval Program. The company described LIBERTY and DECLARATION as the basis for that planned submission, while clinical efficacy data would be unblinded later subject to clinical event accrual.

Nasdaq valuation remains measurable

The last quoted Nasdaq price was USD 0.65 on October 13, 2026 at 4:00 p.m. ET. The 52-week range was USD 0.53 to USD 3.07, while the market capitalization was USD 190.3 million on that date. The company therefore combines a measurable commercial base with a valuation still tied closely to the next clinical readout.